A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies

Journal of General Virology

Volumn 86, Issue 5, 2005, Pages 1435-1440

  Faber, Milosz ^a   Lamirande, Elaine W ^b   Roberts, Anjeanette ^b   Rice, Amy B ^a   Koprowski, Hilary ^a   Dietzschold, Bernhard ^a   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; THROMBOSPONDIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS SPIKE PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG SAFETY; ERADICATION THERAPY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES VIRUS; RHABDOVIRUS; RISK REDUCTION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY; ZOONOSIS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DNA-DIRECTED RNA POLYMERASES; FEMALE; GENETIC VECTORS; GLYCOPROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEUTRALIZATION TESTS; NUCLEOCAPSID PROTEINS; RHABDOVIRIDAE; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

ANIMALIA; CORONAVIRUS; RABIES VIRUS; RHABDOVIRIDAE; SARS CORONAVIRUS; SARS COV;

EID: 18144427091     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80844-0     Document Type: Article

References (31)

1. Aubert, M. F. A., Masson, E., Artois, M. & Barrat, J. (1994). Oral wildlife rabies vaccination field trails in Europe with recent emphasis on France. In Lyssaviruses, pp. 219-243. Edited by C. E. Rupprecht, B. Dietzschold & H. Koprowski. Berlin, Heidelberg, New York: Springer.
2. Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P. L., Murphy, B. R., Subbarao, K. & Moss, B. (2004). Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 101, 6641-6646. (Epub 2004 Apr 19).
3. Dietzschold, B., Faber, M. & Schnell, M. J. (2003). New approaches to the prevention and eradication of rabies. Expert Rev Vaccines 2, 399-406.
4. Drosten, C., Gunther, S., Preiser, W. & 23 other authors (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348, 1967-1976.
5. Foley, H. D., McGettigan, J. P., Slier, C. A., Dietzschold, B. & Schnell, M. J. (2000). A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci U S A 97, 14680-14685.
6. Foley, H. D., Otero, M., Orenstein, J. M., Pomerantz, R. J. & Schnell, M. J. (2002). Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol 76, 19-31.
7. Guan, Y., Zheng, B. J., He, Y. Q. & 15 other authors (2003). Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276-278.
8. Holmes, K. V. (2003). SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111, 1605-1609.
9. Lafon, M., Lafage, M., Martinez-Arends, A., Ramirez, R., Vuillier, F., Charron, D., Lotteau, V. & Scott-Algara, D. (1992). Evidence for a viral superantigen in humans. Nature 358, 507-510.
10. McGettigan, J. P., Foley, H. D., Belyakov, I. M., Berzofsky, J. A., Pomerantz, R. J. & Schnell, M. J. (2001a). Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 75, 4430-4434.
11. McGettigan, J. P., Sarma, S., Orenstein, J. M., Pomerantz, R. J. & Schnell, M. J. (2001b). Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol 75, 8724-8732.
12. McGettigan, J. P., Naper, K., Orenstein, J., Koser, M., McKenna, P. M. & Schnell, M. J. (2003a). Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol 77, 10889-10899.
13. McGettigan, J. P., Pomerantz, R. J., Slier, C. A., McKenna, P. M., Foley, H. D., Dietzschold, B. & Schnell, M. J. (2003b). Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77, 237-244.
14. McKenna, P. M., Pomerantz, R. J., Dietzschold, B., McGettigan, J. P. & Schnell, M. J. (2003). Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J Virol 77, 12782-12794.
15. Meslin, F.-X., Fishbein, D. B. & Matter, H. C. (1994). Rationale and prospects for rabies elimination in developing countries. In Lyssaviruses, pp. 1-26. Edited by B. D. C. E. Rupprecht & H. Koprowski. Berlin, Heidelberg, New York: Springer.
16. Morimoto, K., Foley, H. D., McGettigan, J. P., Schnell, M. J. & Dietzschold, B. (2000). Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J Neurovirol 6, 373-381.
17. Morimoto, K., McGettigan, J. P., Foley, H. D., Hooper, D. C., Dietzschold, B. & Schnell, M. J. (2001a). Genetic engineering of live rabies vaccines. Vaccine 19, 3543-3551.
18. Morimoto, K., Schnell, M. J., Pulmanausahakul, R., McGettigan, J. P., Foley, H. D., Faber, M., Hooper, D. C. & Dietzschold, B. (2001b). High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods 252, 199-206.
19. Orciari, L. A., Niezgoda, M., Hanlon, C. A., Shaddock, J. H., Sanderlin, D. W., Yager, P. A. & Rupprecht, C. E. (2001). Rapid clearance of SAG-2 rabies virus from dogs after oral vaccination. Vaccine 19, 4511-4518.
20. Peiris, J. S., Lai, S. T., Poon, L. L. & 14 other authors (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325.
21. Reed, L. J. & Muench, H. (1938). A simple method of estimating fifty percent endpoints. Am J Hyg 27, 493-497.
22. Rota, P. A., Oberste, M. S., Monroe, S. S. & 32 other authors (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394-1399.
23. Rupprecht, C. E., Hanlon, C. A., Niezgoda, M., Murphy, S., Schnell, M. J. & Dietzschold, B. (2001). Oral rabies vaccination of the mongoose, Herpestes auropunctatus. In Rabies in the Americas. XII International Meeting on Advances in Rabies Research and Control in the Americas. Peterborough, Ontario, Canada.
24. Rupprecht, C. E., Hanlon, C. A., Blanton, J. & 7 other authors (2005). Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res (in press).
25. Schnell, M. J., Mebatsion, T. & Conzelmann, K. K. (1994). Infectious rabies viruses from cloned cDNA. EMBO J 13, 4195-4203.
26. Schnell, M. J., Foley, H. D., Slier, C. A., McGettigan, J. P., Dietzschold, B. & Pomerantz, R. J. (2000). Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A 97, 3544-3549.
27. Shoji, Y., Inoue, S., Nakamichi, K., Kurane, I., Sakai, T. & Morimoto, K. (2004). Generation and characterization of P gene-deficient rabies virus. Virology 318, 295-305.
28. Siler, C. A., McGettigan, J. P., Dietzschold, B., Herrine, S. K., Dubuisson, J., Pomerantz, R. J. & Schnell, M. J. (2002). Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292, 24-34.
29. Subbarao, K., McAuliffe, J., Vogel, L. & 7 other authors (2004). Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78, 3572-3577.
30. Wiktor, T. J., Macfarlan, R. I., Foggin, C. M. & Koprowski, H. (1984). Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand 57, 199-211.
31. Yang, Z. Y., Kong, W. P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K. & Nabel, G. J. (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561-564.